EMA Backing Unlikely for MaaT Pharma's Microbiota Therapy After Negative Trend Vote

The European Medicines Agency's human medicines committee (CHMP) has issued a negative trend vote for MaaT Pharma's microbiota-based therapy, Xervyteg (MaaT013), after re-examining a previous negative opinion for its EU marketing application. This indicates that EU marketing approval is unlikely for the investigational therapy for acute graft-versus-host disease.